These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22664810)

  • 1. Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study.
    Thakkar AS; Abhyankar AD; Dani SI; Banker DN; Singh PI; Parmar SA; Mehta AA
    Indian Heart J; 2012; 64(3):273-9. PubMed ID: 22664810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study.
    Wiemer M; Seth A; Chandra P; Neuzner J; Richardt G; Piek JJ; Desaga M; Macaya C; Bol CJ; Miquel-Hebert K; De Roeck K; Serruys PW
    Am Heart J; 2008 Oct; 156(4):751.e1-7. PubMed ID: 18926156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of biodegradable polymer-coated sirolimus-eluting stents in unselected real-world population with coronary artery disease: results from the multicenter CORE Registry.
    Banker D; Ahuja A; Sanadhya H; Purohit C; Chandra S; Sethi R; Khare R; Kothari S; Thakkar A
    Minerva Cardioangiol; 2016 Feb; 64(1):9-14. PubMed ID: 25907696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions.
    Vetrovec GW; Rizik D; Williard C; Snead D; Piotrovski V; Kopia G
    Catheter Cardiovasc Interv; 2006 Jan; 67(1):32-7. PubMed ID: 16342216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study.
    Ostojic M; Sagic D; Jung R; Zhang YL; Nedeljkovic M; Mangovski L; Stojkovic S; Debeljacki D; Colic M; Beleslin B; Milosavljevic B; Orlic D; Topic D; Karanovic N; Paunovic D; Christians U;
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):901-8. PubMed ID: 19016466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus-eluting coronary stent.
    Vishnevetsky D; Patel P; Tijerino H; Gandhi PJ
    Am J Health Syst Pharm; 2004 Mar; 61(5):449-56. PubMed ID: 15018222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Supralimus sirolimus-eluting stent.
    Lemos PA; Bienert I
    Expert Rev Med Devices; 2013 May; 10(3):295-300. PubMed ID: 23597097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease.
    Stojkovic S; Neskovic AN; Mehmedbegovic Z; Kafedzic S; Ostojic M; Nedeljkovic M; Orlic D; Ilisic B; Ilic I; Aleksic A; Cerovic M; Nikolajevic I; Vlahovic-Stipac A; Stajic Z; Putnikovic B; Hamilos M
    Fundam Clin Pharmacol; 2015 Feb; 29(1):95-105. PubMed ID: 25223651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects.
    Nakamura M; Otsuka Y; Ueda Y; Mitsudo K
    Cardiovasc Interv Ther; 2012 Jan; 27(1):24-30. PubMed ID: 24122637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients.
    Sinha SK; Aggarwal P; Pandey U; Razi M; Kumar A; Krishna V
    Anatol J Cardiol; 2021 Feb; 25(2):111-119. PubMed ID: 33583818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender-specific outcomes after sirolimus-eluting stent implantation.
    Solinas E; Nikolsky E; Lansky AJ; Kirtane AJ; Morice MC; Popma JJ; Schofer J; Schampaert E; Pucelikova T; Aoki J; Fahy M; Dangas GD; Moses JW; Cutlip DE; Leon MB; Mehran R
    J Am Coll Cardiol; 2007 Nov; 50(22):2111-6. PubMed ID: 18036446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study.
    Dani S; Kukreja N; Parikh P; Joshi H; Prajapati J; Jain S; Thanvi S; Shah B; Dutta JP
    EuroIntervention; 2008 May; 4(1):59-63. PubMed ID: 19112780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo assessment of stent recoil of biodegradable polymer-coated cobalt-chromium sirolimus-eluting coronary stent system.
    Abhyankar AD; Thakkar AS
    Indian Heart J; 2012; 64(6):541-6. PubMed ID: 23253404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
    Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
    Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
    Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seven-year clinical outcomes in patients undergoing percutaneous coronary intervention with biodegradable polymer coated sirolimus-eluting stent: Results from a single-center real-world experience.
    Abhyankar A; Kaul U; Sinha SK
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S280-S284. PubMed ID: 30595275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.